Baili Tianheng (688506.SH): BL-M14D1 (DLL3ADC) combined immunotherapy for first-line extensive-stage small cell lung cancer patients III clinical trial application approved by the FDA.

Zhtng cijng APP xn, bil tin hng (688506.SH) fb gnggo, gngs de qunz zgngs SystImmune, Inc. jnr shudo migu shpn yof jjin gunl j (yxi jinchng "FDA") de tngzh, BL-M14D1(DLL3ADC) linh min d zhlio yngy yxin gunggung q xiob xubi fi'i hunzh de III q lnghu shyn shnqng y hud FDA xk. Zhtng cijng APP news, Baoli Tianheng (688506.SH) announced that its wholly-owned subsidiary SystImmune, Inc. has recently received a notification from the Food and Drug Administration (FDA) of the United States. The application for Phase III clinical trial of BL-M14D1 (DLL3ADC) combination immunotherapy for first-line extensive stage small cell lung cancer patients has been approved by the FDA.